



Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares

October 3, 2017

WALTHAM, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the closing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of \$17.00 per share. The gross proceeds from the initial public offering to Deciphera were approximately \$127,500,000, before underwriting discounts and estimated offering expenses.

The underwriters also exercised their option to purchase 666,496 additional shares of common stock at the public offering price of \$17.00 per share, bringing total gross proceeds from the offering to approximately \$138,830,432, before underwriting discounts and estimated offering expenses. Such purchase of additional shares is expected to close on October 4, 2017, subject to customary closing conditions.

J.P. Morgan and Piper Jaffray & Co. acted as joint book-running managers for the offering. JMP Securities LLC acted as lead manager and Nomura Securities International, Inc. acted as a co-manager for the offering.

A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on September 27, 2017. The offering was made only by means of a prospectus. A copy of the final

prospectus relating to the offering was filed with the Securities and Exchange Commission on September 28, 2017 and may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by telephone at (866) 803-9204, or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at emailprospectus@pjc.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Deciphera

Deciphera is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

Media Contact:

Gina Nugent, The Yates Network

gina@theyatesnetwork.com

617-460-3579

Investor Relations:

Laura Perry or Sam Martin, Argot Partners

Laura@argotpartners.com or Sam@argotpartners.com

212-600-1902

Company Contact:

Christopher J. Morl, Chief Business Officer

Deciphera Pharmaceuticals, LLC

cmorl@deciphera.com

781-209-6418

 [Primary Logo](#)

Source: Deciphera Pharmaceuticals LLC